All AbMole products are for research use only, cannot be used for human consumption.
Miltefosine inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa, first oral compound for Visceral leishmaniasis, effective against both promastigotes and amastigotes.
Molecular Weight | 407.57 |
Formula | C21H46NO4P |
CAS Number | 58066-85-6 |
Solubility (25°C) | DMSO |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Jaime A Soto, et al. Miltefosine Treatment of Cutaneous Leishmaniasis
[4] Paulo R L Machado, et al. Miltefosine and cutaneous leishmaniasis
Related Akt Products |
---|
ZINC00784494
ZINC00784494 is a specific Lipocalin-2 (LCN2) inhibitor. ZINC00784494 inhibits cell proliferation, cell viability and reduces AKT phosphorylation levels in SUM149 cells. |
(E)-Akt inhibitor-IV
(E)-Akt inhibitor-IV is a PI3K-Akt inhibitor, with potent cytotoxic. |
K-80003
K-80003 is a potent inhibitor of tRXRα-dependent Akt activation and cancer cell growth. |
FPA-124
FPA-124, a cell-permeable copper complex, is a selective Akt inhibitor with an IC50 of 0.1 μM. |
SPOP-IN-1
SPOP-IN-1 is a selective SPOP E3 ubiquitin ligase inhibitor. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.